Novo Nordisk shares fall after $23 billion 2030 obesity sales target
The company's long-range guidance for its obesity franchise landed below investor expectations, sending the stock lower.
TR
By Tom Reyes · Markets Editor
Sep 21 08:26 ETSource: Yahoo Finance
The wire
- 01Novo Nordisk set a roughly $23 billion obesity sales target for 2030, and its shares dropped after the disclosure.
- 02The guidance frames how aggressively the maker of semaglutide expects to defend share against tirzepatide and next-generation incretins, with implications for pricing and supply.
- 03The report does not break out contributions by product or geography; targets are company projections, not results.
From the source
Read at finance.yahoo.comNovo Nordisk Shares Sink After $23 Billion Obesity Sales Target for 2030